The company's lead products include anti-cancer natural human antibodies for the treatment of multiple cancers, and it also develops various human antibody discovery programs in infectious diseases. Patrys has collaborations with AstraZeneca/Cambridge Antibody Technology and Debiopharm S.A. and is exploring opportunities to use its technologies in other disease areas. Patrys is publicly listed on the Australian Securities Exchange and has two technology platforms: IgM monoclonal antibodies and a suite of nuclear penetrating antibodies for cancer therapy.